Key Takeaway
Percutaneous ozone therapy for herniated disc-related low back pain shows positive results with low morbidity, earning evidence level II-1 for paravertebral injection and II-3 for intradiscal injection, though no placebo-controlled trials existed at time of review.
Summary
This systematic review and meta-analysis evaluated ozone therapy for low back pain caused by disc herniation, searching electronic databases from 1966 through September 2011.
Eight observational studies and four randomized controlled trials were analyzed. Intradiscal ozone injection received evidence level II-3 with recommendation grade 1C, while paravertebral ozone injection demonstrated stronger evidence at level II-1 with recommendation grade 1B.
The authors concluded that percutaneous ozone therapy yields positive results with low morbidity rates for chronic low back pain, though significant methodological limitations temper the strength of these findings.
Methods
- Systematic review and meta-analysis of RCTs
- Database search from 1966 through September 2011
- Quality assessment using modified Cochrane criteria and AHRQ standards
- Primary outcome: pain relief at 6 months (short-term) and beyond (long-term)
Key Results
- 8 observational studies and 4 RCTs analyzed
- Intradiscal ozone: evidence level II-3, recommendation grade 1C
- Paravertebral ozone: evidence level II-1, recommendation grade 1B
- Positive pain relief outcomes with low morbidity rates
Limitations
- No placebo-controlled trials available
- Imprecise diagnoses across included studies
- Mixed therapeutic agents used in some studies
- Predominantly active-control trial designs